GT Biopharma
GTBP
GTBP
35 hedge funds and large institutions have $3.05M invested in GT Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
46% less capital invested
Capital invested by funds: $5.63M → $3.05M (-$2.58M)
Holders
35
Holding in Top 10
–
Calls
$4K
Puts
$1K
Top Buyers
| 1 | +$320K | |
| 2 | +$20.4K | |
| 3 | +$12.7K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.32K |
| 5 |
Millennium Management
New York
|
+$6.09K |
Top Sellers
| 1 | -$654K | |
| 2 | -$111K | |
| 3 | -$11.8K | |
| 4 |
Jane Street
New York
|
-$1.81K |
| 5 |
Rockefeller Capital Management
New York
|
-$1K |